Exercise of stock
options settled
in cash - (286) - -
---------------------------------------------- --------------------------
(2,878) (11,245) (83) (2,214)
---------------------------------------------- --------------------------
Investing activities
Purchase of property
and equipment (143) (28) (10) (17)
Increase in
intangible assets - (277) - (277)
Proceeds from
loan receivable - 800 - -
---------------------------------------------- --------------------------
(143) 495 (10) (294)
---------------------------------------------- --------------------------
Financing activities
Issuance of
share capital - 10,907 - -
Proceeds from
exercise of
stock options - 201 - -
---------------------------------------------- --------------------------
- 11,108 - -
---------------------------------------------- --------------------------
Increase (decrease)
in cash and cash
equivalents (3,021) 358 (93) (2,508)
Cash and cash
equivalents,
beginning of period 15,077 16,616 12,149 19,482
---------------------------------------------- --------------------------
---------------------------------------------- --------------------------
Cash and cash
equivalents,
end of period $ 12,056 $ 16,974 $ 12,056 $ 16,974
-------------------
'/>"/>
| SOURCE Cipher Pharmaceuticals Inc. Copyright©2007 PR Newswire. All rights reserved |